NCT06192784View on ClinicalTrials.gov

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 9, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

June 30, 2025

Conditions
Cholangiocarcinoma Non-resectable
Interventions
PROCEDURE

DEB-TACE

transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.

DRUG

Lenvatinib plus pucotenlimab

lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Geneplus-Beijing Co. Ltd.

INDUSTRY

collaborator

Chinese Cooperative Group of Liver Cancer

OTHER

lead

Tongji Hospital

OTHER